NEW YORK (GenomeWeb) — OncoSec Medical, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it is working with the University of California, Los Angeles and PerkinElmer to develop molecular biomarkers to measure patients' immune responses to cancer.

OncoSeq said that the effort will use PerkinElmer’s imaging-based staining methods to quantitatively evaluate CD8+ T cell density, with the goal of developing markers that can distinguish responders from non-responders to anti-PD-1 monotherapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.